Discovery of brain permeable 2-Azabicyclo[2.2.2]octane sulfonamides as a novel class of presenilin-1 selective γ-secretase inhibitors. 2023

Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
Discovery Chemistry, Therapeutics Discovery, Janssen Research & Development, Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340, Beerse, Belgium; KU Leuven, Department of Neurosciences, Leuven Institute for Neuroscience and Disease, (LIND), Leuven, Belgium. Electronic address: rajnarlawar@gmail.com.

This paper describes the rational design, synthesis, structure-activity relationship (SAR), and biological profile of presenilin-1 (PSEN-1) complex selective γ-secretase inhibitors, assessed for selectivity using a unique set of four γ-secretase subtype complexes. A set of known PSEN-1 selective γ-Secretase inhibitors (GSIs) was analyzed to understand the pharmacophoric features required for selective inhibition. Conformational modeling suggests that a characteristic 'U' shape orientation between aromatic sulfone/sulfonamide and aryl ring is crucial for PSEN-1 selectivity and potency. Using these insights, a series of brain-penetrant 2-azabicyclo[2,2,2]octane sulfonamides was devised and synthesized as a new class of PSEN-1 selective inhibitors. Compounds 13c and 13k displayed high potency towards PSEN1-APH1B complex but moderate selectivity towards PSEN2 complexes. However, compound (+)-13b displayed low nanomolar potency towards the PSEN1-APH1B complex, little (∼4-fold) selectivity towards PSEN1-APH1A, and high selectivity (>350-fold) versus PSEN2 complexes. Excellent brain penetration, no significant CYP inhibition, or cardiotoxicity, good solubility, and permeability make (+)-13b an excellent candidate for further lead optimization.

UI MeSH Term Description Entries
D009795 Octanes Eight-carbon saturated hydrocarbon group of the methane series. Include isomers and derivatives. Isooctanes
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D000077145 Sulfanilamide A short-acting sulfonamide used as an anti-infective agent. It has lower anti-bacterial activity than SULFAMETHOXAZOLE. 4-aminobenzenesulfonamide,Azol Polvo,Sulfanilamide Barium Salt,Sulfanilamide Cadmium Salt,Sulfanilamide Hydrochloride,Sulfanilamide Lithium Salt,Sulfanilamide Magnesium Salt,Sulfanilamide Monohydrate,Sulfanilamide Silver Salt,Sulfanilamide Sodium,Sulfanilamide Sodium Salt,Sulfanilamide Strontium Salt,Sulfanilamide Zinc Salt,Sulphanilamide,4 aminobenzenesulfonamide
D013449 Sulfonamides A group of compounds that contain the structure SO2NH2. Sulfonamide,Sulfonamide Mixture,Sulfonamide Mixtures,Mixture, Sulfonamide,Mixtures, Sulfonamide
D053764 Presenilin-1 Integral membrane protein of Golgi and endoplasmic reticulum. Its homodimer is an essential component of the gamma-secretase complex that catalyzes the cleavage of membrane proteins such as NOTCH RECEPTORS and AMYLOID BETA-PEPTIDES precursors. PSEN1 mutations cause early-onset ALZHEIMER DISEASE type 3 that may occur as early as 30 years of age in humans. Presenilin 1,S182 Protein
D053829 Amyloid Precursor Protein Secretases Endopeptidases that are specific for AMYLOID PROTEIN PRECURSOR. Three secretase subtypes referred to as alpha, beta, and gamma have been identified based upon the region of amyloid protein precursor they cleave. APP Secretase,Amyloid Precursor Protein Secretase,Secretase,Secretases,alpha-Secretase,beta-Secretase,gamma-Secretase,Secretase, APP,alpha Secretase,beta Secretase,gamma Secretase

Related Publications

Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
June 2011, Biochemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
March 1966, Journal of medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
March 1966, Journal of medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
August 2009, Bioorganic & medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
July 1973, Journal of medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
May 2008, The Journal of organic chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
June 1976, Journal of medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
October 1974, Journal of pharmaceutical sciences,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
September 1969, Journal of medicinal chemistry,
Rajeshwar Narlawar, and Lutgarde Serneels, and Celia Gaffric, and Harrie J M Gijsen, and Bart De Strooper, and François Bischoff
September 2021, Journal of medicinal chemistry,
Copied contents to your clipboard!